Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has recommended continuation of its ongoing Phase 3 clinical trial of buntanetap in …
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate a Phase 2b dose-optimization trial …
Medicus Pharma Receives FDA Clearance to Begin Phase 2b Teverelix Study Read More
PHILADELPHIA, PA — Aro Biotherapeutics reported interim data from a Phase 1b study of ABX1100, an investigational therapy for late-onset Pompe disease, showing the drug was generally well tolerated and …
Experimental Pompe Therapy Shows Early Promise in Trial Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2b clinical study of Teverelix, a long-acting …
FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) said the U.S. Food and Drug Administration has cleared its investigational new drug application for PRT12396, allowing the company to begin a …
FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders Read More
EXTON, PA — Frontage Laboratories, Inc. announced a major expansion of its early phase clinical research capabilities across the United States and China, positioning the company to meet surging demand …
Frontage Scales Global Phase I Reach as Patent Cliff Accelerates Drug Trials Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ATI-2138, showing rapid, near-complete, and sustained hair regrowth in a severe mouse model …
Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study Read More
NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) said it has completed enrollment in a 90-patient Phase 2 study testing its experimental oral COVID-19 treatment ratutrelvir against PAXLOVID®, reporting early …
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones Read More PHILADELPHIA, PA — Aro Biotherapeutics said it will present interim clinical data next month from its ongoing Phase 1b trial of ABX1100, an experimental therapy aimed at treating late-onset Pompe …
Experimental Pompe Therapy Shows Early Signal Ahead of Key San Diego Reveal Read More